CWEB

Why Do You Have To Be Careful With TransEnterix Stock TransEnterix, ( TRXC ) Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. According to recent studies Robotic assisted minimally invasive surgery does not appear to offer any clinical benefits over conventional laparoscopic techniques in terms of outcomes and complication rates but is associated with significantly higher costs, two new studies of cancers indicate. TransEnterix surgical bot, Senhance, only does laparoscopic surgery. The Senhance is an old surgical robot, approved in Europe in 2011, and only three have been sold by TransEnterix in Europe. This report will likely have negative implications for TransEnterix financial top and bottom lines. <iframe width="560" height="315" src="https://www.youtube.com/embed/9TXBP1t2rUc" frameborder="0" allow="autoplay; encrypt...

Why Is AYTU A Strong Buy And Potential Buy Out By Leslie CohenManaging Editor Aytu BioScience, Inc.AYTU  ( OTC:AYTU )  is a small-cap stock operating in the pharmaceutical industry dedicated to improving Urological health for men worldwide. The Company addresses problems like insomnia, male infertility, and hypogonadism. Their portfolio of products included Natesto , Zolpimist, and MiOXSYS® Aytu BioScience  ( OTC:AYTU )  Enters $1.8 Billion U.S. Prescription Sleep Aid Market with Exclusive License to Zolpimist(NYSE: TM ) to Expand Company's Commercial-Stage Product Portfolio Natesto is the first FDA-approved intranasal testosterone replacement therapy. ZOLPIMIST™ (zolpidem tartrate) Oral Spray, the only FDA-approved oral spray zolpidem product indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation and is available both in the US and internationally. Zolpidem tartrate has been shown to decrease the time i...

Netflix: Loyal Subscribers Love Netflix- And So Does Wall Street By: Leslie Cohen Great news for Netflix, Inc. ( NFLX ) as it will replace Monsanto in the S&P 100. Monsanto is being acquired by BAYER (BAY.TI). Netflix’s stock closed up 1.1% to $365.80 on Tuesday, June 5 th  2018. The way we view entertainment has changed. Kannan Venkateshwar, media analyst of Barclays Capital states, “ We believe the economics for companies with global streaming scale like Netflix may be more favorable than theatrical releases, over time.” Netflix has given control over to the consumer on how they watch movies. And- consumer are loving it. It gives the viewer a wide choice of content that is viewable any time- on demand, and on any device. What’s not to love about Netflix? “13 Reasons Why” one of Netflix’s most popular shows drawing an audience in the second season of an average audience of 2.6 million viewers in the U.S. , all within the first three days on air, according...

CWEB.com - Why Neovasc Inc Is A Very Dangerous Stock  Neovasc Inc (NASDAQ, TSX: NVCN) a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Legal actions are still not settled and may impede future cash flows. Projections of net income losses bring into question liquidity problems. Industry competitiveness and consolidation will bring on a new set of challenges. "Remaining on the Nasdaq Capital Market ("Nasdaq") is a critical piece of the Company's turnaround strategy," commented Fred Colen , Neovasc's President and Chief Executive Officer. "Without reaching a minimum bid...